Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib.

Shayan OwjiStella A CaldasBenjamin Ungar

Published in: Journal of asthma and allergy (2022)

Atopic dermatitis (AD) is a common chronic, pruritic inflammatory skin disease that profoundly impacts patients' quality of life. As the first FDA-approved topical JAK inhibitor, ruxolitinib 1.5% cream represents a novel therapeutic topical agent for the treatment of AD. The objective of this review is to summarize the efficacy and safety of ruxolitinib cream in patients with AD based on the available evidence. Overall, ruxolitinib cream demonstrated high efficacy and a favorable safety profile for treating atopic dermatitis.

Keyphrases

atopic dermatitis
end stage renal disease
wound healing
ejection fraction
newly diagnosed
peritoneal dialysis
oxidative stress
prognostic factors
soft tissue
drug induced
patient reported